EuropaBio’s first Biomanufacturing Policy Summit will set the vision for Europe’s global innovation, competitiveness and sustainability through the lens of biomanufacturing and set a baseline for its understanding and recognition within policy.
The half day meeting will bring together Members and invited stakeholders from across the policy, finance, trade, skills and regulatory spectrum surrounding biomanufacturing.
Discussion will address what biomanufacturing looks like across sectors and the roles played by SMEs, large companies and expert services. The economic and skills footprint will be reviewed, plus how it sits within Europe’s twin pillars of green and digital transition within the industrial strategy. Finally, it can start to address how policy shapes and facilitates biomanufacture and Europe’s global position for such a transformative technology in action.
From the first Summit, a roadmap for biomanufacture can be developed for Europe and creation of a long term discussion platform for stakeholders through the Platform.
|14:00||Welcome and introduction to the Biomanufacturing Policy Summit|
– Claire Skentelbery, Director General, EuropaBio
|14:10||Biomanufacturing in Europe’s industrial transition|
– Peter Dröll, Director Prosperity, European Commission, DG Research and Innovation
|14:30||Biomanufacturing as a global transition: US Executive Order for Biomanufacturing in focus|
– Hilary Stiss, Director, International Affairs, Biotechnology Innovation Organization (BIO)
|14:45||Quo vadis European Biomanufacturing innovation in a competitive, globalized world|
– Wojciech Nowak, Global Senior Director, Novartis
|15:00||I am Biomanufacturing: examples in action|
● Resilience, sustainability and competitiveness: Biomanufacturing in daily life: Ute Schick, Senior Vice President Research, Development and Innovation (RDI), Nutrition & Care (NC-RDI), Evonik Operations GmbH
● Growing SMEs: Biomanufacturing in the next generation of industry: Jeroen Hofenk, Founder and Chief Science Officer, SwiftPharma
● The national landscape: Belgium’s economic development through biomanufacturing: Tineke Van hooland, Deputy Secretary General Bio.be
● Advanced healthcare: The role of biomanufacturing in reaching rare diseases: Philippe Moyen, VP, Chief of Staff to CTOO and Head of CMC Program Management – Technical Operations, PTC Therapeutics
|16:00||Parallel Breakout discussions|
|Breakout 1 – Advanced healthcare: Role and growth in Europe|
● Role in Europe’s pandemic response. Scale and flexibility of manufacture – planning, delivering, investment
● Patient access to advanced therapies (including rare diseases).
● Competitiveness and economic contributor across Europe
|Breakout 2 – Resilience, competitiveness and sustainability:|
● Transition of industrial process for sustainability
● Building resilience of supply
● Innovation for competitiveness
Closing panel discussion: Europe’s ambition and pathway for biomanufacturing
Stakeholders from across the biomanufacturing landscape look at the future for Europe within biomanufacturing. The industrial goals it must achieve, the pathway towards those goals and how it can make use of the skills, infrastructure and policy/regulatory frameworks through which Europe develops.
Moderator: Kristin Schreiber (Director DG GROW)
Panelists: Peter Wehrheim (Head of Unit RTD.B2), Kristin Thompson (COO EUREKARE), Nessa Fennelly (Senior Executive IBEC), Nicolo Giacomuzzi-Moore (Executive Director CBE JU), Stefaan Fiers (Head of Corporate Communication, Public Affairs and Patient Advocacy Takeda Belgium).
Director, International Affairs, BIO Program Director, ICBA
As a Director for International Affairs at the Biotechnology Innovation Organization (BIO), Hilary is responsible for managing the industry association’s program of international advocacy and outreach for multilateral organizations. Hilary also manages the association’s engagement in Europe, the Middle East, North Africa, Turkey and South Africa regions. In this position, she engages with foreign officials in these regions to promote policies that support a strong biotechnology industry as well as to resolve policy issues relevant to the industry. Hilary also acts as Program Director for the International Council on Biotechnology Associations (ICBA).
Claire holds a PhD in biochemistry and has worked in the development of scientific networks and associations for over 15 years. She started her career as part of the Cambridge biotech cluster in the UK within the cluster business network and was a founder of the Council of European BioRegions, a network of biotech clusters across Europe. She brought herself and CEBR to Brussels in 2009 where she also took on the role of SG for the European Biotechnology Network, working across sectors, organisations and countries as part of the EBN mission to facilitate partnerships. In January 2017, Claire took up her role as DG of the Nanotechnology Industries Association which she successfully led until recently.
Senior Vice President Research, Development and Innovation, Evonik
Dr. Schick has a 20-year track record in global profit and loss responsibility at CEO and Senior Manager level within Food, Health, Cosmetic Industry and Material Science. Before her current role with Evonik, she held roles as SVP of Supply Chain and Business Processes and VP of new Growth Business. Prior to working at Evonik she held roles at DuPont and DSM.
Group Senior Director, Global Governmental and Public Affairs, Novartis International, Switzerland.
(Functional responsibility for ca. 30 countries incl. Western & Eastern Europe, Central Asia).
Multicultural, inclusive and reflective leader who lived in 6 countries on 3 continents.
Robust understanding of the global healthcare policies and life-sciences business with more than 20 years of experience in policy creation related to healthcare systems, EU integration and global pharmaceutical market.
Started his career at the Ministry of Health (Poland) counselling policy leaders on European integration and healthcare matters, followed by assignments in the Ministry of Health and Solidarity of the Republic of France (Paris, France) and Health Directorate of the European Commission (DG SANCO, Luxembourg).
After joining private sector has been serving in a number of senior leadership roles of growing
responsibility in healthcare companies(GlaxoSmithKline, Abbott, Novartis) on country, regional and global levels (Poland, Belgium, Switzerland).
Educated in Poland, United States, Nederlands, Switzerland, with the background in political sciences, international relations (Warsaw’s University, Poland; European Institute of Public Administration, Maastricht, Nederlands) and business administration (IMD Business School Lausanne, Switzerland) he is an expert in healthcare systems, global healthcare policies and international business.
Passionate about delivering access and best healthcare outcomes to patients around the World.
Deputy Secretary general of bio.be/essenscia
Tineke Van Hooland is Deputy Secretary general of bio.be/essenscia, the Belgian federation of companies active in life sciences & biotechnologies. She’s also a board member at EuropaBio, the European Association for Bioindustries, from which she also chairs the NAC, National Associations Council. Prior to this, Tineke held several leadership positions in biopharmaceutical companies at the corporate level over the past years. She has in-depth expertise in Governmental Affairs, Market Access, Communication and Patient Advocacy. Tineke graduated with High Distinction as Industrial Pharmacist from Ghent University in 2003.
Tineke is also the founder and CEO of epic 10, a boutique external affairs consultancy firm, and a respected board member in various other organizations. She is known for her dynamic and no-nonsense approach, is a female leadership advocate and has authored a number of opinion pieces on sustainable health policy and empowering women.
Kristin Schreiber leads the Directorate Ecosystems I: Chemicals, Food, Retail, Health in DG GROW, the Directorate General for Internal Market, Industry, Entrepreneurship and SMEs.
Prior to her current Director position, she served as Director for Governance of the Single Market and International Affairs in DG MARKT (until 2015) and Director for SME policy in DG GROW (until March 2021).
Kristin Schreiber was Head of Cabinet of Employment Commissioner Vladimir Špidla, Deputy Head of Cabinet of Internal Market Commissioner Michel Barnier and member of the Cabinets of Enlargement Commissioner Günter Verheugen and Competition Commissioner Karel Van Miert. She also served as Head of Unit for International Affairs in DG Employment and Social Affairs and was a member of the Merger Task Force of DG Competition.
Corporate Communications, Public Affairs and Patient Advocacy Takeda
Stefaan is Head of Corporate Communications, Public Affairs and Patient Advocacy at Takeda Belgium, one of the largest pharmaceutical companies in Belgium. With his team, he secures the healthcare policy analysis, engages with external stakeholders and coordinates the company’s communication strategy. Additionally, he oversees Takeda’s public affairs activities in 24 mid-sized European countries.
Before joining Takeda in June 2020, he was Director of Communications and Public Policy at the Belgian pharma industry association pharma.be and held public policy positions in the pharma industry, at Bristol-Myers Squibb Belgium/Luxembourg and at MSD Belgium.
Next to his activities at Takeda, Stefaan is an Associate Professor in Public Affairs and Comparative Politics at KU Leuven, a Board member of PACE (Public Affairs Community Europe), and the author of several books and peer-reviewed articles.
VP, Chief of Staff to CTOO and Head of CMC Program Management – Technical Operations, PTC Therapeutics
Following a university focus on therapeutic systems, followed by formulation and industrial development, Philippe has worked across the biotechnology spectrum including Baxter Healthcare, Fresenius Kabi, Stallergenes Greer, and PTC Therapeutics where he has a strong focus on operations.
VP, Chief Business Officer
Kristin Thompson is a former head of strategic partnerships in microbiomes at Bioaster. Before that, Dr. Thompson was senior BD manager at Famar and BD manager of the French biotech company DaVolterra. She worked in research at French INSERM and the University of North Carolina, Chapel Hill. She holds a Ph.D. in molecular biology from the University of Ulm, Germany.
Executive Director ad interim, Circular Bio-based Industries Joint Undertaking
Nicoló Giacomuzzi-Moore is CBE JU’s Executive Director ad interim and Head of the Administration and Finance Unit. He has been working in European affairs for more than 20 years, focusing on research and innovation policy, program implementation, and enterprise support.
Before joining BBI JU (now CBE JU) in 2016, he worked for the European Commission’s Research Executive Agency, where he was responsible for financial and legal support in implementing European research projects.
Nicoló also worked for an Italian business association dealing with industrial policy and stakeholder management at the EU level. He holds a degree in economics and international trade.
Director for Prosperity, Directorate-General for Research and Innovation
Peter Dröll has been working in the European Commission for more than 20 years with positions in the environment, enlargement negotiations, industry policy, innovation, and research. He was a Cabinet member of Enlargement Commissioner Günter Verheugen and Head of Cabinet of the Science and Research Commissioner Janez Potočnik.
Since 2010 he is at the Directorate-General of Research and Innovation where he was first responsible for Innovation and then for Industrial Technologies. Following the re-orientation of DG Research and Innovation towards sustainability, his competencies have been enlarged to include industrial R&I agendas and business intelligence as well as knowledge valorization policies.
Before joining the European Commission in 1991, Peter worked as a lawyer in a German law firm. Peter is a lawyer by training with a doctorate degree in German constitutional law and European law.
Founder and Chief Science Officer, SwiftPharma
Jeroen is a serial entrepreneur and scientist with a background in bioengineering and genetics. He has broad experience in CRISPR engineering and various expression platforms including microbial-, animal cell-based, and plants. In the last 10 years of his career, Jeroen has built a strong track record in plant-made-pharmaceutical manufacturing and the optimization thereof. He obtained 3 patent grants and holds 13 pending patents to his name.”
Head of the Unit for the “Bioeconomy and Food System” within the Directorate General for Research and Innovation of the European Commission in Brussels
While working for Phil Hogan, Commissioner for Agriculture and Rural Development, he contributed to the EU Bioeconomy Strategy. From 2010 to 2018 he was Head of the Unit for Land Use and Climate Finance in DG Climate Action. Before 2004 Peter worked at the Universities of Bonn/DE, Maryland/US (with a Heisenberg scholarship from the German Research Foundation), and Kiel/DE. He received his doctoral degree in agricultural economics from the University of Giessen, Germany
About the EuropaBio Biomanufacturing Platform
The Platform has the mission to represent biomanufacturing at the highest policy levels in Europe, to ensure that it is visible and recognised within the industrial strategy and Europe’s green and digital transitions.
EuropaBio’s Biomanufacturing Platform will address the policy and wider frameworks through which biomanufacturing is delivered. Together with members and stakeholders, it will address how economic growth, employment and resilience are achieved through policy, legal frameworks and regulation at EU and national levels.
The Summit will be open to EuropaBio Members and invited stakeholders. Please contact email@example.com for further information.
+32 2 735 03 13